The Effects Of Liraglutide Treatment On Type2Diabetes With Cardiovascular Risk Factors

Objective:This study aims to investigate the effects of liraglutide on type2diabetespatients with cardiovascular risk factors and evaluate its efficacy and safety for thepurpose of exploring the treatment strategies for type2diabetes accompanying withcardiovascular disease.Method:56patients with type2diabetes were involved from April2012to October2012in the China-Japan Union Hospital of Jilin University Xinmin Branch and randomizedinto Liralutide treatment group and the control group. Liraglutide treatment groupinvolved28patients with a mean age of47.8±8.9years and mean disease-process of5.2±2.8years. The patients in liraglutide treatment group were given GLP-1Ragonist liraglutide treatment on the basis of Insulin Aspart30Injection therapy.0.6mgliralutide was injected daily in first week, and then the dose increased to1.2mg.Insulin dose was adjusted according to the blood glucose monitoring. The controlgroup involved28patients with a mean age of48.1±10.7years and meandisease-process of5.0±3.0years. The patients in control group were given InsulinAspart30Injection therapy, and insulin dose was adjusted according to the bloodglucose monitoring. After16weeks’ therapy, we observed the changes of body massindex (BMI), waist circumference (W), waist-to-hip ratio (WHR), systolic bloodpressure (SBP), diastolic bood pressure (DBP), glycosylated hemoglobin A1c(HbA1c), fasting plasma glucose (FPG),2-hour postprandial blood glucose(2hPG), HOMA2-IR, C-reactive protein(CRP), total cholesterol (TC), triglyceride(TG)，high-density lipoprotein (HDL-c) and low-density lipoprotein cholesterol (LDL-c). SPSS19.0statistical software was applied for statistical analysis.Results:1. Liraglutide could decrease HbA1c and2hPG (compared with baseline, p<0.01)and both of them are significantly different from control group (p<0.05); andliraglutide could reduce FPG level (compared with baseline, p<0.01) but there is nosignificant differences between liraglutide group and control group (p>0.05).2. Liraglutide treatment could reduce BMI, waist circumference and WHR(compared with baseline, p<0.01), while they are also significantly different fromcontrol group (p<0.05).3. Liraglutide could decrease CRP levels (compared with baseline, p<0.01) andit’s significantly different between liraglutide group and control group (p<0.01).4. Liraglutide could decrease TC and TG levels (compared with baseline,p<0.01), but there is no significant differences between liraglutide group and controlgroup (p>0.05). While liraglutide could increase HDL-C levels (compared withbaseline, p<0.01) but decrease LDL-C levels (compared with baseline, p<0.01), andboth of them are significantly different from control group (p<0.05).5. Liraglutide could significantly decrease SBP and DBP (compared withbaseline, p<0.01), and SBP is significantly different between liraglutide group andcontrol group (p<0.05).Conclusion:Liraglutide could improve cardiovascular risk factors in type2diabetes patients:1. Liraglutide could significantly decrease HbA1c and2hPG. levels;2. Liraglutide could significantly improve BMI, waist circumference and WHR;3. Liraglutide could significantly decrease CRP levels;4. Liraglutide could significantly improve LDL-c and HDL-c;5. Liraglutide could significantly decrease SBP.